Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. BACKGROUND:Atherosclerosis is the most common cause of cardiovascular diseases. Clinical studies indicate that loss-of-function ASGR1 (asialoglycoprotein receptor 1) is significantly associated with lower plasma cholesterol levels and reduces cardiovascular disease risk. However, the effect of ASGR1 on atherosclerosis remains incompletely understood; whether inhibition of ASGR1 causes liver injury remains controversial. Here, we comprehensively investigated the effects and the underlying molecular mechanisms of ASGR1 deficiency and overexpression on atherosclerosis and liver injury in mice.METHODS:We engineeredAsgr1knockout mice (Asgr1−/−),Asgr1andApoEdouble-knockout mice (Asgr1−/−ApoE−/−), and ASGR1-overexpressing mice on anApoE−/−background and then fed them different diets to assess the role of ASGR1 in atherosclerosis and liver injury.RESULTS:After being fed a Western diet for 12 weeks,Asgr1−/−ApoE−/−mice exhibited significantly decreased atherosclerotic lesion areas in the aorta and aortic root sections, reduced plasma VLDL (very-low-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol levels, decreased VLDL production, and increased fecal cholesterol contents. Conversely, ASGR1 overexpression inApoE−/−mice increased atherosclerotic lesions in the aorta and aortic root sections, augmented plasma VLDL cholesterol and LDL cholesterol levels and VLDL production, and decreased fecal cholesterol contents. Mechanistically, ASGR1 deficiency reduced VLDL production by inhibiting the expression of MTTP (microsomal triglyceride transfer protein) and ANGPTL3 (angiopoietin-like protein 3)/ANGPTL8 (angiopoietin-like protein 8) but increasing LPL (lipoprotein lipase) activity, increased LDL uptake by increasing LDLR (LDL receptor) expression, and promoted cholesterol efflux through increasing expression of LXRα (liver X receptor-α), ABCA1 (ATP-binding cassette subfamily A member 1), ABCG5 (ATP-binding cassette subfamily G member 5), and CYP7A1 (cytochrome P450 family 7 subfamily A member 1). These underlying alterations were confirmed in ASGR1-overexpressingApoE−/−mice. In addition, ASGR1 deficiency exacerbated liver injury in Western diet–inducedAsgr1−/−ApoE−/−mice and high-fat diet–induced but not normal laboratory diet–induced and high-fat and high-cholesterol diet–inducedAsgr1−/−mice, while its overexpression mitigated liver injury in Western diet–induced ASGR1-overexpressingApoE−/−mice.CONCLUSIONS:Inhibition of ASGR1 inhibits atherosclerosis in Western diet–fedApoE−/−mice, suggesting that inhibiting ASGR1 may serve as a novel therapeutic strategy to treat atherosclerosis and cardiovascular diseases.

ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity

ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice

ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet–Fed ApoE−/− Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux

Deficiency of ASGR1 Alleviates Diet-Induced Systemic Insulin Resistance via Improved Hepatic Insulin Sensitivity

Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR that is shed by Furin

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin

Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic endoplasmic reticulum stress

Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans

ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor

Adipokine gremlin-1 promotes hepatic steatosis via upregulation of ER stress by suppressing autophagy-mediated signaling

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

Anterior gradient 2 increases long-chain fatty acid uptake via stabilizing FABP1 and facilitates lipid accumulation

Beyond conventional treatment: ASGR1 Leading the new era of hypercholesterolemia management

The serum soluble ASGR1 concentration is elevated in patients with coronary artery disease and is associated with inflammatory markers

The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation

Lipodystrophic gene Agpat2 deficiency aggravates hyperlipidemia and atherosclerosis in Ldlr mice

Serglycin Is Involved in Adipose Tissue Inflammation in Obesity

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes

Liver-specific Glucocorticoid Action in Alcoholic Liver Disease: Study of Glucocorticoid Receptor Knockout and Knockin Mice